利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1090 条记录 (耗时 0.025 秒)

    FORTIFIED PLANT-BASED FORMULATIONS
    82.
    发明申请
    FORTIFIED PLANT-BASED FORMULATIONS 有权

    公开(公告)号：US20210120859A1

    公开(公告)日：2021-04-29

    申请号：US16927442

    申请日：2020-07-13

    申请人： iVolution Organic Whole Foods Inc.

    发明人： Delphine BOILLOT ,  Christian MARINARO

    IPC分类号： A23L33/00 ,  A23L33/15 ,  A23L33/12 ,  A23L33/105

    摘要： The present technology relates to a fortified plant-based formulation suitable for administration to a subject. The fortified plant-based formulation comprises, at least one vitamin component; at least one lipid component; at least one protein component; and at least one calcium-source component, wherein the at least one calcium-source component is an algae, and is present in the fortified plant-based formulation in an amount ranging from between about 0.5 to about 4 wt %.

    Exogenous ketone supplements for reducing anxiety-related behavior
    83.
    发明授权
    Exogenous ketone supplements for reducing anxiety-related behavior 有权

    公开(公告)号：US10980764B1

    公开(公告)日：2021-04-20

    申请号：US15422091

    申请日：2017-02-01

    申请人： University of South Florida

    发明人： Csilla Ari D'Agostino ,  Dominic Paul D'Agostino

    IPC分类号： A61K31/22 ,  A61K31/23 ,  A61K31/19 ,  A61K9/00 ,  A23L33/00 ,  A23L33/16 ,  A23L33/12

    摘要： Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and/or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood βHB levels and changed blood glucose levels.

    R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
    84.
    发明授权
    R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions 有权

    公开(公告)号：US10973786B2

    公开(公告)日：2021-04-13

    申请号：US16996509

    申请日：2020-08-18

    申请人： AXCESS GLOBAL SCIENCES, LLC

    发明人： Gary Millet

    IPC分类号： A61K31/19 ,  A61K47/14 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61P3/08 ,  A23L29/00 ,  A23L33/12 ,  A23L33/00 ,  A23L33/10 ,  A23L33/155

    摘要： Beta-hydroxybutyrate (BHB) mixed salts are formulated to induce or sustain ketosis in a subject. The BHB mixed salts provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. BHB mixed salt compositions include two, three or four of sodium BHB, potassium BHB, calcium BHB, or magnesium BHB. BHB mixed salt compositions include R-BHB and/or S-BHB, such as enriched with either R-BHB or S-BHB. BHB mixed salt compositions may include BHB mixed salts and beta-hydroxybutyric acid. BHB mixed salts may be provided as or mixed with a dietetically or pharmaceutically acceptable carrier. BHB mixed salt compositions can be a solid, such as a powder, or a liquid, such as a beverage. A mixed salt-acid composition is particularly well-suited for flavored beverages.

    FREE POLYUNSATURATED FATTY ACID-CONTAINING COMPOSITION AND MANUFACTURING METHOD THEREFOR
    85.
    发明申请
    FREE POLYUNSATURATED FATTY ACID-CONTAINING COMPOSITION AND MANUFACTURING METHOD THEREFOR 有权

    公开(公告)号：US20210102142A1

    公开(公告)日：2021-04-08

    申请号：US17124636

    申请日：2020-12-17

    申请人： NIPPON SUISAN KAISHA, LTD.

    发明人： Yuhei KOSUGE ,  Hideaki YAMAGUCHI ,  Nobushige DOISAKI

    IPC分类号： C11C3/00 ,  A23D9/007 ,  C07C69/58 ,  C07C57/12 ,  A61K31/201 ,  A61K31/202 ,  A23L33/12

    摘要： The present disclosure is: a free polyunsaturated fatty acid-containing composition, which comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, the content being at least 80.0% of the fatty acids in the composition, and satisfies at least one selected from a group consisting of conditions (1) and (2): (1) the content of conjugated unsaturated fatty acid is 1.0% or less of the fatty acids in the composition, and (2) the Gardner color is less than 3+; and a manufacturing method for the free polyunsaturated fatty acid-containing composition comprising the preparation of a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms, and hydrolysis of a reaction solution containing the prepared raw material composition, a lower alcohol, water and an alkali catalyst at a temperature of 10° C. or lower.

    LYMPHATIC CIRCULATION IMPROVING AGENTS
    87.
    发明申请
    LYMPHATIC CIRCULATION IMPROVING AGENTS 有权

    公开(公告)号：US20210077447A1

    公开(公告)日：2021-03-18

    申请号：US16968321

    申请日：2019-02-08

    申请人： NIPPON SUISAN KAISHA, LTD.

    发明人： Kenichi YANAGIMOTO ,  Li HAN ,  Bungo SHIROUCHI

    IPC分类号： A61K31/202 ,  A61P7/10 ,  A61K31/232 ,  A23L33/12 ,  A23L33/00

    摘要： The present invention provides a composition for improving lymphatic circulation, which contains a component selected from at least one highly unsaturated fatty acid, salt thereof, and ester thereof as an active ingredient. The present invention also provides a composition for improving lymphatic circulation, which contains as active ingredients a triglyceride comprising the at least one highly unsaturated fatty acid as a constituent fatty acid and a triglyceride comprising the at least one middle chain fatty acid as a constituent fatty acid. The present invention also provides a composition for improving lymphatic circulation, which contains as an active ingredient a triglyceride comprising the at least one highly unsaturated fatty acid and the at least one middle chain fatty acid as constituent fatty acids.

    ORAL ADMINISTRATION FORMULATION OF BLUEBERRY EXTRACT AS A COADJUVANT FOR PRESERVING THE HEALTH OF HUMAN PRECORNEAL FILM
    88.
    发明申请
    ORAL ADMINISTRATION FORMULATION OF BLUEBERRY EXTRACT AS A COADJUVANT FOR PRESERVING THE HEALTH OF HUMAN PRECORNEAL FILM 有权

    公开(公告)号：US20210076726A1

    公开(公告)日：2021-03-18

    申请号：US16954401

    申请日：2018-12-18

    申请人： CENTRO DE RETINA MEDICA Y QUIRURGICA, S.C.

    发明人： Arturo SANTOS GARCIA ,  Juan Carlos ALTAMIRANO VALLEJO ,  Jose Alonso CHAVEZ GARCIA ,  Alejandro GONZALEZ DE LA ROSA

    IPC分类号： A23L33/19 ,  A23L33/155 ,  A23L33/105 ,  A23L33/12

    摘要： The invention relates to a nutraceutical formulation of blueberry extract, fish oil (omega-3 and omega-6), recombinant human lactoferrin, vitamin A and vitamin E, for human oral consumption. The invention belongs to the field of ophthalmology and has been developed as a coadjuvant for preserving the health of the precorneal film and of the eye surface. This formulation contains an extract of natural origin (Vaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film. No formulation for oral administration of a blueberry extract together with lactoferrin, in combination with vitamin A, vitamin E and fish oil (eicosapentaenoic acid and docosahexaenoic acid) is found in the prior art, nor is the use of this formulation as an adjuvant for preserving the health of the precorneal film and/or the eye surface.